The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities

Abstract

The NLRP3 inflammasome is a pivotal signaling platform of the innate immune system that senses a broad spectrum of microbial, metabolic, and environmental danger signals. Its activation leads to the recruitment of ASC and caspase-1, driving the maturation of pro-inflammatory cytokines interleukin (IL)-1β and IL-18 as well as the execution of pyroptosis. Aberrant or persistent activation of NLRP3 has been implicated in the pathogenesis of numerous disorders, including autoinflammatory syndromes, metabolic and cardiovascular diseases, neurodegenerative conditions, and cancers. In this review, we provide an updated overview of the molecular mechanisms governing NLRP3 activation and regulation, with particular focus on ion flux, mitochondrial damage, lysosomal rupture, reactive oxygen species, and post-translational modifications. We further discuss negative regulatory pathways that maintain inflammasome homeostasis and prevent excessive inflammation. Finally, we summarize recent advances in therapeutic strategies targeting the NLRP3 inflammasome, ranging from direct inhibitors and allosteric modulators to biologics and repurposed drugs, and highlight their translational potential. Understanding the fine balance between NLRP3 activation and inhibition offers new opportunities for therapeutic intervention in a wide array of inflammatory and immune-related diseases.

Keywords

activation mechanisms / inflammatory diseases / innate immunity / NLRP3 inflammasome / therapeutic inhibitors

References

[1] R. Medzhitov and C. Janeway, “Innate Immune Recognition: Mechanisms and Pathways,” Immunological Reviews 173 (2000): 89–97.

[2] T. Kawai and S. Akira, “The Roles of TLRs, RLRs and NLRs in Pathogen Recognition,” International Immunology 21 (2009): 317–337.

[3] J. P. Ting, R. C. Lovering, E. S. Alnemri, et al., “The NLR Gene Family: A Standard Nomenclature,” Immunity 28 (2008): 285–287.

[4] H. M. Hoffman, J. L. Mueller, D. H. Broide, A. A. Wanderer, and R. D. Kolodner, “Mutation of a New Gene Encoding a Putative Pyrin-Like Protein Causes Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome,” Nature Genetics 29 (2001): 301–305.

[5] K. V. Swanson, M. Deng, and J. P. Ting, “The NLRP3 Inflammasome: Molecular Activation and Regulation to Therapeutics,” Nature Reviews Immunology 19 (2019): 477–489.

[6] F. Zhu, J. Ma, W. Li, et al., “The Orphan Receptor Nur77 Binds Cytoplasmic LPS to Activate the Non-Canonical NLRP3 Inflammasome,” Immunity 56 (2023): 753–767.

[7] E. Viganò, C. E. Diamond, R. Spreafico, A. Balachander, R. M. Sobota, and A. Mortellaro, “Human Caspase-4 and Caspase-5 Regulate the One-Step Non-Canonical Inflammasome Activation in Monocytes,” Nature Communications 6 (2015): 8761.

[8] B. Lagrange, S. Benaoudia, P. Wallet, et al., “Human Caspase-4 Detects Tetra-Acylated LPS and Cytosolic Francisella and Functions Differently From Murine Caspase-11,” Nature Communications 9 (2018): 242.

[9] M. M. Gaidt and V. Hornung, “Alternative Inflammasome Activation Enables IL-1β Release From Living Cells,” Current Opinion in Immunology 44 (2017): 7–13.

[10] F. G. Bauernfeind, G. Horvath, A. Stutz, et al., “Cutting Edge: NF-kappaB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression,” Journal of Immunology 183 (2009): 787–791.

[11] N. Song, Z. S. Liu, W. Xue, et al., “NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation,” Molecular Cell 68 (2017): 185–197.

[12] R. Muñoz-Planillo, P. Kuffa, G. Martínez-Colón, B. L. Smith, T. M. Rajendiran, and G. Núñez, “K⁺ Efflux Is the Common Trigger of NLRP3 Inflammasome Activation by Bacterial Toxins and Particulate Matter,” Immunity 38 (2013): 1142–1153.

[13] V. Pétrilli, S. Papin, C. Dostert, A. Mayor, F. Martinon, and J. Tschopp, “Activation of the NALP3 Inflammasome Is Triggered by Low Intracellular Potassium Concentration,” Cell Death and Differentiation 14 (2007): 1583–1589.

[14] Z. Xu, Z. M. Chen, X. Wu, L. Zhang, Y. Cao, and P. Zhou, “Distinct Molecular Mechanisms Underlying Potassium Efflux for NLRP3 Inflammasome Activation,” Frontiers in Immunology 11 (2020): 609441.

[15] A. Di, S. Xiong, Z. Ye, et al., “The TWIK2 Potassium Efflux Channel in Macrophages Mediates NLRP3 Inflammasome-Induced Inflammation,” Immunity 49 (2018): 56–65.

[16] G. S. Lee, N. Subramanian, A. I. Kim, et al., “The Calcium-Sensing Receptor Regulates the NLRP3 Inflammasome Through Ca2+ and cAMP,” Nature 492 (2012): 123–127.

[17] T. Murakami, J. Ockinger, J. Yu, et al., “Critical Role for Calcium Mobilization in Activation of the NLRP3 Inflammasome,” PNAS 109 (2012): 11282–11287.

[18] T. Tang, X. Lang, C. Xu, et al., “CLICs-Dependent Chloride Efflux Is an Essential and Proximal Upstream Event for NLRP3 Inflammasome Activation,” Nature Communications 8 (2017): 202.

[19] J. P. Green, S. Yu, F. Martín-Sánchez, et al., “Chloride Regulates Dynamic NLRP3-Dependent ASC Oligomerization and Inflammasome Priming,” PNAS 115 (2018): E9371–e9380.

[20] V. Hornung, F. Bauernfeind, and A. Halle, “Silica Crystals and Aluminum Salts Activate the NALP3 Inflammasome Through Phagosomal Destabilization,” Nature Immunology 9 (2008): 847–856.

[21] K. Rajamäki, J. Lappalainen, K. Oörni, et al., “Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link Between Cholesterol Metabolism and Inflammation,” PLoS ONE 5 (2010): e11765.

[22] Q. Ma and C. S. Lim, “Molecular Activation of NLRP3 Inflammasome by Particles and Crystals: A Continuing Challenge of Immunology and Toxicology,” Annual Review of Pharmacology and Toxicology 64 (2024): 417–433.

[23] J. Chen and Z. J. Chen, “PtdIns4P on Dispersed trans-Golgi Network Mediates NLRP3 Inflammasome Activation,” Nature 564 (2018): 71–76.

[24] N. A. Schmacke, F. O'Duill, M. M. Gaidt, et al., “IKKβ Primes Inflammasome Formation by Recruiting NLRP3 to the Trans-Golgi Network,” Immunity 55 (2022): 2271–2284.

[25] Z. Zhang, R. Venditti, L. Ran, et al., “Distinct Changes in Endosomal Composition Promote NLRP3 Inflammasome Activation,” Nature Immunology 24 (2023): 30–41.

[26] J. P. Green, T. Swanton, L. V. Morris, et al., “LRRC8A is Essential for Hypotonicity-, But Not for DAMP-Induced NLRP3 Inflammasome Activation,” eLife 9 (2020): e59704.

[27] X. Zhan, Q. Li, G. Xu, X. Xiao, and Z. Bai, “The Mechanism of NLRP3 Inflammasome Activation and Its Pharmacological Inhibitors,” Frontiers in Immunology 13 (2022): 1109938.

[28] Z. Xu, A. J. Kombe Kombe, S. Deng, et al., “NLRP Inflammasomes in Health and Disease,” Molecular Biomedicine 5 (2024): 14.

[29] J. Fu and H. Wu, “Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation,” Annual Review of Immunology 41 (2023): 301–316.

[30] A. M. Casey, D. G. Ryan, H. A. Prag, et al., “Pro-Inflammatory Macrophages Produce Mitochondria-Derived Superoxide by Reverse Electron Transport at Complex I That Regulates IL-1β Release During NLRP3 Inflammasome Activation,” Nature Metabolism 7 (2025): 493–507.

[31] L. K. Billingham, J. S. Stoolman, K. Vasan, et al., “Mitochondrial Electron Transport Chain Is Necessary for NLRP3 Inflammasome Activation,” Nature Immunology 23 (2022): 692–704.

[32] Q. Lin, S. Li, N. Jiang, et al., “PINK1-Parkin Pathway of Mitophagy Protects Against Contrast-Induced Acute Kidney Injury via Decreasing Mitochondrial ROS and NLRP3 Inflammasome Activation,” Redox Biology 26 (2019): 101254.

[33] M. Xie, Y. Yu, R. Kang, et al., “PKM2-Dependent Glycolysis Promotes NLRP3 and AIM2 Inflammasome Activation,” Nature Communications 7 (2016): 13280.

[34] W. C. Chou, E. Rampanelli, X. Li, and J. P. Ting, “Impact of Intracellular Innate Immune Receptors on Immunometabolism,” Cellular and Molecular Immunology 19 (2022): 337–351.

[35] X. Li, S. Thome, X. Ma, et al., “MARK4 regulates NLRP3 Positioning and Inflammasome Activation Through a Microtubule-Dependent Mechanism,” Nature Communications 8 (2017): 15986.

[36] S. Paik, J. K. Kim, P. Silwal, C. Sasakawa, and E. K. Jo, “An Update on the Regulatory Mechanisms of NLRP3 Inflammasome Activation,” Cellular and Molecular Immunology 18 (2021): 1141–1160.

[37] G. M. Tannahill, A. M. Curtis, J. Adamik, et al., “Succinate Is an Inflammatory Signal That Induces IL-1β Through HIF-1α,” Nature 496 (2013): 238–242.

[38] D. Wang, M. Wang, S. Sun, et al., “Hypoxia-Induced NLRP3 Inflammasome Activation via the HIF-1α/NF-κB Signaling Pathway in human Dental Pulp Fibroblasts,” BMC Oral Health 24 (2024): 1156.

[39] C. G. Peace and L. A. O'Neill, “The Role of Itaconate in Host Defense and Inflammation,” Journal of Clinical Investigation 132 (2022): e148548.

[40] E. A. Day and L. A. J. O'Neill, “Protein Targeting by the Itaconate Family in Immunity and Inflammation,” Biochemical Journal 479 (2022): 2499–2510.

[41] M. A. Gianfrancesco, J. Dehairs, L. L'Homme, et al., “Saturated Fatty Acids Induce NLRP3 Activation in Human Macrophages Through K(+) Efflux Resulting From Phospholipid Saturation and Na, K-ATPase Disruption,” Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids 1864 (2019): 1017–1030.

[42] Y. H. Youm, K. Y. Nguyen, R. W. Grant, et al., “The Ketone Metabolite β-Hydroxybutyrate Blocks NLRP3 Inflammasome-Mediated Inflammatory Disease,” Nature Medicine 21 (2015): 263–269.

[43] M. M. Mank, K. A. Zoller, V. A. Fastiggi, J. L. Ather, and M. E. Poynter, “Acidosis Licenses the NLRP3 Inflammasome-Inhibiting Effects of Beta-Hydroxybutyrate and Short-Chain Carboxylic Acids,” BioRxiv (2025).

[44] Z. Su, J. Lan, Y. Wang, et al., “Lactylation-Driven ALKBH5 Diminishes Macrophage NLRP3 Inflammasome Activation in Patients With G6PT Deficiency,” Journal of Allergy and Clinical Immunology 155 (2025): 1783–1799.

[45] F. Yu, Y. Meng, X. Wang, et al., “Protein Lactylation of Citrate Synthase Promotes the AKI-CKD Transition by Activating the NLRP3 Inflammasome,” Cell Reports 44 (2025): 116084.

[46] R. Xu, L. S. Yuan, Y. Q. Gan, et al., “Potassium Ion Efflux Induces Exaggerated Mitochondrial Damage and Non-Pyroptotic Necrosis When Energy Metabolism Is Blocked,” Free Radical Biology and Medicine 212 (2024): 117–132.

[47] Y. Wang, J. Lu, A. F. Carisey, et al., “Innate Immune and Metabolic Signals Induce Mitochondria-Dependent Membrane Lysis via Mitoxyperiosis,” Cell 188 (2025): 7155–7174.

[48] A. G. Lerner, J. P. Upton, P. V. Praveen, et al., “IRE1α Induces Thioredoxin-Interacting Protein to Activate the NLRP3 Inflammasome and Promote Programmed Cell Death Under Irremediable ER Stress,” Cell Metabolism 16 (2012): 250–264.

[49] Z. Pu, W. Wang, H. Xie, and W. Wang, “Apolipoprotein C3 (ApoC3) Facilitates NLRP3 Mediated Pyroptosis of Macrophages Through Mitochondrial Damage by Accelerating of the Interaction Between SCIMP and SYK Pathway in Acute Lung Injury,” International Immunopharmacology 128 (2024): 111537.

[50] M. Cescato, Y. Y. Zhu, L. L. Corre, B. F. Py, S. Georgin-Lavialle, and M. P. Rodero, “Implication of the LRR Domain in the Regulation and Activation of the NLRP3 Inflammasome,” Cells 13 (2024): 1365.

[51] L. Xiao, V. G. Magupalli, and H. Wu, “Cryo-EM Structures of the Active NLRP3 Inflammasome Disc,” Nature 613 (2023): 595–600.

[52] H. F. Lu, Y. C. Zhou, T. Y. Hu, et al., “Unraveling the Role of NLRP3 Inflammasome in Allergic Inflammation: Implications for Novel Therapies,” Frontiers in Immunology 15 (2024): 1435892.

[53] H. Sharif, L. Wang, W. L. Wang, et al., “Structural Mechanism for NEK7-Licensed Activation of NLRP3 Inflammasome,” Nature 570 (2019): 338–343.

[54] Y. Kim, S. Lee, and Y. H. Park, “NLRP3 Negative Regulation Mechanisms in the Resting State and Its Implications for Therapeutic Development,” International Journal of Molecular Sciences 25 (2024): 9018.

[55] L. Andreeva, L. David, S. Rawson, and H. Wu, Full-length NLRP3 Forms Oligomeric Cages to Mediate NLRP3 Sensing and Activation (Cold Spring Harbor Laboratory, 2021).

[56] U. Ohto, Y. Kamitsukasa, H. Ishida, et al., “Structural Basis for the Oligomerization-Mediated Regulation of NLRP3 Inflammasome Activation,” PNAS 119 (2022): e2121353119.

[57] M. S. Dick, L. Sborgi, S. Rühl, S. Hiller, and P. Broz, “ASC Filament Formation Serves as a Signal Amplification Mechanism for Inflammasomes,” Nature Communications 7 (2016): 11929.

[58] D. Boucher, M. Monteleone, R. C. Coll, et al., “Caspase-1 Self-cleavage Is an Intrinsic Mechanism to Terminate Inflammasome Activity,” Journal of Experimental Medicine 215 (2018): 827–840.

[59] I. V. Hochheiser, H. Behrmann, G. Hagelueken, et al., “Directionality of PYD Filament Growth Determined by the Transition of NLRP3 Nucleation Seeds to ASC Elongation,” Science Advances 8 (2022): eabn7583.

[60] R. C. Coll, J. R. Hill, C. J. Day, et al., “MCC950 Directly Targets the NLRP3 ATP-Hydrolysis Motif for Inflammasome Inhibition,” Nature Chemical Biology 15 (2019): 556–559.

[61] N. Kayagaki, S. Warming, M. Lamkanfi, et al., “Non-Canonical Inflammasome Activation Targets Caspase-11,” Nature 479 (2011): 117–121.

[62] J. L. Schmid-Burgk, M. M. Gaidt, T. Schmidt, T. S. Ebert, E. Bartok, and V. Hornung, “Caspase-4 Mediates Non-Canonical Activation of the NLRP3 Inflammasome in Human Myeloid Cells,” European Journal of Immunology 45 (2015): 2911–2917.

[63] J. Shi, Y. Zhao, K. Wang, et al., “Cleavage of GSDMD by Inflammatory Caspases Determines Pyroptotic Cell Death,” Nature 526 (2015): 660–665.

[64] S. Rühl and P. Broz, “Caspase-11 Activates a Canonical NLRP3 Inflammasome by Promoting K(+) Efflux,” European Journal of Immunology 45 (2015): 2927–2936.

[65] M. M. Gaidt, T. S. Ebert, D. Chauhan, et al., “Human Monocytes Engage an Alternative Inflammasome Pathway,” Immunity 44 (2016): 833–846.

[66] C. C. Hsu, B. Shao, J. E. Kanter, et al., “Apolipoprotein C3 Induces Inflammasome Activation Only in Its Delipidated Form,” Nature Immunology 24 (2023): 408–411.

[67] S. Zewinger, J. Reiser, V. Jankowski, et al., “Apolipoprotein C3 Induces Inflammation and Organ Damage by Alternative Inflammasome Activation,” Nature Immunology 21 (2020): 30–41.

[68] J. Yang, Z. Liu, and T. S. Xiao, “Post-Translational Regulation of Inflammasomes,” Cellular and Molecular Immunology 14 (2017): 65–79.

[69] T. Kodi, R. Sankhe, A. Gopinathan, K. Nandakumar, and A. Kishore, “New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation,” Journal of Neuroimmune Pharmacology 19 (2024): 7.

[70] X. Liu, X. Zhang, Y. Ding, et al., “Nuclear Factor E2-Related Factor-2 Negatively Regulates NLRP3 Inflammasome Activity by Inhibiting Reactive Oxygen Species-Induced NLRP3 Priming,” Antioxidants and Redox Signaling 26 (2017): 28–43.

[71] C. Guo, Z. Chi, D. Jiang, et al., “Cholesterol Homeostatic Regulator SCAP-SREBP2 Integrates NLRP3 Inflammasome Activation and Cholesterol Biosynthetic Signaling in Macrophages,” Immunity 49 (2018): 842–856.

[72] P. Ma, S. Zha, X. Shen, et al., “NFAT5 Mediates Hypertonic Stress-Induced Atherosclerosis via Activating NLRP3 Inflammasome in Endothelium,” Cell Communication and Signaling 17 (2019): 102.

[73] S. Wang, Y. Lin, X. Yuan, F. Li, L. Guo, and B. Wu, “REV-ERBα Integrates Colon Clock With Experimental Colitis Through Regulation of NF-κB/NLRP3 Axis,” Nature Communications 9 (2018): 4246.

[74] L. Zhu, Q. Meng, S. Liang, et al., “The Transcription Factor GFI1 Negatively Regulates NLRP3 Inflammasome Activation in Macrophages,” FEBS Letters 588 (2014): 4513–4519.

[75] W. Huai, R. Zhao, H. Song, et al., “Aryl Hydrocarbon Receptor Negatively Regulates NLRP3 Inflammasome Activity by Inhibiting NLRP3 Transcription,” Nature Communications 5 (2014): 4738.

[76] M. M. McDaniel, L. C. Kottyan, H. Singh, and C. Pasare, “Suppression of Inflammasome Activation by IRF8 and IRF4 in cDCs Is Critical for T Cell Priming,” Cell Reports 31 (2020): 107604.

[77] J. Kaszycki and M. Kim, “Epigenetic Regulation of Transcription Factors Involved in NLRP3 Inflammasome and NF-kB Signaling Pathways,” Frontiers in Immunology 16 (2025): 1529756.

[78] M. Wei, L. Wang, T. Wu, et al., “NLRP3 Activation Was Regulated by DNA Methylation Modification During Mycobacterium Tuberculosis Infection,” BioMed Research International 2016 (2016): 4323281.

[79] X. Guan, R. Liu, B. Wang, et al., “Inhibition of HDAC2 Sensitises Antitumour Therapy by Promoting NLRP3/GSDMD-Mediated Pyroptosis in Colorectal Cancer,” Clinical and Translational Medicine 14 (2024): e1692.

[80] Y. Xiao, C. Zhao, Y. Tai, et al., “STING Mediates Hepatocyte Pyroptosis in Liver Fibrosis by Epigenetically Activating the NLRP3 Inflammasome,” Redox Biology 62 (2023): 102691.

[81] C. Jimenez Calvente, H. Del Pilar, M. Tameda, C. D. Johnson, and A. E. Feldstein, “MicroRNA 223 3p Negatively Regulates the NLRP3 Inflammasome in Acute and Chronic Liver Injury,” Molecular Therapy 28 (2020): 653–663.

[82] T. H. Akbaba, Y. Z. Akkaya-Ulum, E. D. Batu, et al., “Dysregulation of miRNA-30e-3p Targeting IL-1β in an International Cohort of Systemic Autoinflammatory Disease Patients,” Journal of Molecular Medicine 101 (2023): 757–766.

[83] Q.-B. Zhang, D. Zhu, F. Dai, et al., “MicroRNA-223 Suppresses IL-1β and TNF-α Production in Gouty Inflammation by Targeting the NLRP3 Inflammasome,” Frontiers in Pharmacology 12 (2021): 2021.

[84] M. E. O'Keefe, G. R. Dubyak, and D. W. Abbott, “Post-Translational Control of NLRP3 Inflammasome Signaling,” Journal of Biological Chemistry 300 (2024): 107386.

[85] Z. Liang, A. Damianou, E. Di Daniel, and B. M. Kessler, “Inflammasome Activation Controlled by the Interplay Between Post-Translational Modifications: Emerging Drug Target Opportunities,” Cell Communication and Signaling 19 (2021): 23.

[86] S. Han, T. B. Lear, J. A. Jerome, et al., “Lipopolysaccharide Primes the NALP3 Inflammasome by Inhibiting Its Ubiquitination and Degradation Mediated by the SCFFBXL2 E3 Ligase,” Journal of Biological Chemistry 290 (2015): 18124–18133.

[87] S. Beesetti, “Ubiquitin Ligases in Control: Regulating NLRP3 Inflammasome Activation,” Frontiers in Bioscience 30 (2025): 25970.

[88] H. Song, B. Liu, W. Huai, et al., “The E3 Ubiquitin Ligase TRIM31 Attenuates NLRP3 Inflammasome Activation by Promoting Proteasomal Degradation of NLRP3,” Nature Communications 7 (2016): 13727.

[89] B. F. Py, M. S. Kim, H. Vakifahmetoglu-Norberg, and J. Yuan, “Deubiquitination of NLRP3 by BRCC3 Critically Regulates Inflammasome Activity,” Molecular Cell 49 (2013): 331–338.

[90] M. A. Rodgers, J. W. Bowman, H. Fujita, et al., “The Linear Ubiquitin Assembly Complex (LUBAC) Is Essential for NLRP3 Inflammasome Activation,” Journal of Experimental Medicine 211 (2014): 1333–1347.

[91] D. W. Shim and K. H. Lee, “Posttranslational Regulation of the NLR Family Pyrin Domain-Containing 3 Inflammasome,” Frontiers in Immunology 9 (2018): 1054.

[92] C. Guo, S. Xie, Z. Chi, et al., “Bile Acids Control Inflammation and Metabolic Disorder Through Inhibition of NLRP3 Inflammasome,” Immunity 45 (2016): 802–816.

[93] Z. Zhang, G. Meszaros, W. T. He, et al., “Protein Kinase D at the Golgi Controls NLRP3 Inflammasome Activation,” Journal of Experimental Medicine 214 (2017): 2671–2693.

[94] M. R. Spalinger, S. Kasper, C. Gottier, et al., “NLRP3 Tyrosine Phosphorylation Is Controlled by Protein tyrosine Phosphatase PTPN22,” Journal of Clinical Investigation 126 (2016): 4388.

[95] Y. Qin and W. Zhao, “Posttranslational Modifications of NLRP3 and Their Regulatory Roles in Inflammasome Activation,” European Journal of Immunology 53 (2023): e2350382.

[96] R. Barry, S. W. John, G. Liccardi, et al., “SUMO-Mediated Regulation of NLRP3 Modulates Inflammasome Activity,” Nature Communications 9 (2018): 3001.

[97] Y. Zhang, L. Luo, X. Xu, et al., “Acetylation Is Required for Full Activation of the NLRP3 Inflammasome,” Nature Communications 14 (2023): 8396.

[98] A. Mayor, F. Martinon, T. De Smedt, V. Pétrilli, and J. Tschopp, “A Crucial Function of SGT1 and HSP90 in Inflammasome Activity Links Mammalian and Plant Innate Immune Responses,” Nature Immunology 8 (2007): 497–503.

[99] Y. J. Park, N. Dodantenna, Y. Kim, et al., “MARCH5-Dependent NLRP3 Ubiquitination Is Required for Mitochondrial NLRP3-NEK7 Complex Formation and NLRP3 Inflammasome Activation,” EMBO Journal 42 (2023): e113481.

[100] A. C. Pereira, J. De Pascale, R. Resende, et al., “ER-Mitochondria Communication Is Involved in NLRP3 Inflammasome Activation Under Stress Conditions in the Innate Immune System,” Cellular and Molecular Life Sciences 79 (2022): 213.

[101] S. Paik, J. K. Kim, H. J. Shin, E.-J. Park, I. S. Kim, and E.-K. Jo, “Updated Insights Into the Molecular Networks for NLRP3 Inflammasome Activation,” Cellular & Molecular Immunology 22 (2025): 563–596.

[102] V. G. Magupalli, R. Negro, Y. Tian, et al., “HDAC6 Mediates an Aggresome-Like Mechanism for NLRP3 and Pyrin Inflammasome Activation,” Science 369 (2020): eaas8995.

[103] S. Zheng, X. Que, S. Wang, et al., “ZDHHC5-Mediated NLRP3 Palmitoylation Promotes NLRP3-NEK7 Interaction and Inflammasome Activation,” Molecular Cell 83 (2023): 4570–4585.

[104] K. Nakahira, J. A. Haspel, V. A. Rathinam, et al., “Autophagy Proteins Regulate Innate Immune Responses by Inhibiting the Release of Mitochondrial DNA Mediated by the NALP3 Inflammasome,” Nature Immunology 12 (2011): 222–230.

[105] C. S. Shi, K. Shenderov, N. N. Huang, et al., “Activation of Autophagy by Inflammatory Signals Limits IL-1β Production by Targeting Ubiquitinated Inflammasomes for Destruction,” Nature Immunology 13 (2012): 255–263.

[106] X. Wu, L. Gong, L. Xie, et al., “NLRP3 Deficiency Protects Against Intermittent Hypoxia-Induced Neuroinflammation and Mitochondrial ROS by Promoting the PINK1-Parkin Pathway of Mitophagy in a Murine Model of Sleep Apnea,” Frontiers in Immunology 12 (2021): 628168.

[107] J. Harris, M. Hartman, C. Roche, et al., “Autophagy Controls IL-1beta Secretion by Targeting Pro-IL-1beta for Degradation,” Journal of Biological Chemistry 286 (2011): 9587–9597.

[108] C. M. McKee and R. C. Coll, “NLRP3 inflammasome Priming: A Riddle Wrapped in a Mystery inside an Enigma,” Journal of Leukocyte Biology 108 (2020): 937–952.

[109] L. de Almeida, S. Khare, A. V. Misharin, et al., “The PYRIN Domain-only Protein POP1 Inhibits Inflammasome Assembly and Ameliorates Inflammatory Disease,” Immunity 43 (2015): 264–276.

[110] H. T. Le and J. A. Harton, “Pyrin- and CARD-only Proteins as Regulators of NLR Functions,” Frontiers in Immunology 4 (2013): 275.

[111] A. Dorfleutner, L. Chu, and C. Stehlik, “Inhibiting the Inflammasome: One Domain at a Time,” Immunological Reviews 265 (2015): 205–216.

[112] Y. Yan, W. Jiang, L. Liu, et al., “Dopamine Controls Systemic Inflammation Through Inhibition of NLRP3 Inflammasome,” Cell 160 (2015): 62–73.

[113] M. M. Hughes and L. A. J. O'Neill, “Metabolic Regulation of NLRP3,” Immunological Reviews 281 (2018): 88–98.

[114] H. Wen, D. Gris, Y. Lei, et al., “Fatty Acid-induced NLRP3-ASC Inflammasome Activation Interferes With Insulin Signaling,” Nature Immunology 12 (2011): 408–415.

[115] S. Paik, J. K. Kim, H. J. Shin, E. J. Park, I. S. Kim, and E. K. Jo, “Updated Insights Into the Molecular Networks for NLRP3 Inflammasome Activation,” Cellular and Molecular Immunology 22 (2025): 563–596.

[116] J. K. Seok, H. C. Kang, Y. Y. Cho, H. S. Lee, and J. Y. Lee, “Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules,” Frontiers in Immunology 11 (2020): 618231.

[117] L. Agostini, F. Martinon, K. Burns, M. F. McDermott, P. N. Hawkins, and J. Tschopp, “NALP3 forms an IL-1beta-processing Inflammasome With Increased Activity in Muckle-Wells Autoinflammatory Disorder,” Immunity 20 (2004): 319–325.

[118] M. Birk-Bachar, H. Cohen, E. Sofrin-Drucker, et al., “Discovery of a Novel Missense Variant in NLRP3 Causing Atypical Cryopyrin-Associated Periodic Syndromes with Hearing Loss as the Primary Presentation,” Responsive to Anti-Interleukin-1 Therapy, Arthritis and Rheumatology 76 (2024): 444–454.

[119] R. Levy, L. Gérard, J. Kuemmerle-Deschner, et al., “Phenotypic and Genotypic Characteristics of Cryopyrin-associated Periodic Syndrome: A Series of 136 Patients From the Eurofever Registry,” Annals of the Rheumatic Diseases 74 (2015): 2043–2049.

[120] J. Stackowicz, N. Gaudenzio, N. Serhan, et al., “Neutrophil-specific Gain-of-function Mutations in Nlrp3 Promote Development of Cryopyrin-associated Periodic Syndrome,” Journal of Experimental Medicine 218 (2021): e20201466.

[121] U. C. Frising, S. Ribo, M. G. Doglio, B. Malissen, G. van Loo, and A. Wullaert, “Nlrp3 inflammasome Activation in Macrophages Suffices for Inducing Autoinflammation in Mice,” EMBO Reports 23 (2022): e54339.

[122] C. Molina-López, L. Hurtado-Navarro, C. J. García, et al., “Pathogenic NLRP3 Mutants Form Constitutively Active Inflammasomes Resulting in Immune-metabolic Limitation of IL-1β Production,” Nature Communications 15 (2024): 1096.

[123] T. Karasawa, T. Komada, N. Yamada, et al., “Cryo-sensitive Aggregation Triggers NLRP3 Inflammasome Assembly in Cryopyrin-associated Periodic Syndrome,” eLife 11 (2022): e75166.

[124] L. Ran, T. Ye, E. Erbs, et al., “KCNN4 links PIEZO-dependent Mechanotransduction to NLRP3 Inflammasome Activation,” Science Immunology 8 (2023): eadf4699.

[125] J. B. Kuemmerle-Deschner, D. Verma, T. Endres, et al., “Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges,” Arthritis and Rheumatology 69 (2017): 2233–2240.

[126] H. Nakanishi, Y. Kawashima, K. Kurima, et al., “NLRP3 Mutation and Cochlear Autoinflammation Cause Syndromic and Nonsyndromic Hearing Loss DFNA34 Responsive to anakinra Therapy,” PNAS 114 (2017): E7766–E7775.

[127] P. A. Brogan, M. Hofer, J. B. Kuemmerle-Deschner, et al., “Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients with Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger,” Arthritis and Rheumatology 71 (2019): 1955–1963.

[128] J. B. Kuemmerle-Deschner, E. Hachulla, R. Cartwright, et al., “Two-year Results From an Open-label, Multicentre, Phase III Study Evaluating the Safety and Efficacy of canakinumab in Patients With Cryopyrin-associated Periodic Syndrome Across Different Severity Phenotypes,” Annals of the Rheumatic Diseases 70 (2011): 2095–2102.

[129] H. M. Hoffman, M. L. Throne, N. J. Amar, et al., “Efficacy and Safety of Rilonacept (interleukin-1 Trap) in Patients With Cryopyrin-associated Periodic Syndromes: Results From Two Sequential Placebo-controlled Studies,” Arthritis and Rheumatism 58 (2008): 2443–2452.

[130] R. Terkeltaub, J. S. Sundy, H. R. Schumacher, et al., “The Interleukin 1 Inhibitor Rilonacept in Treatment of Chronic Gouty Arthritis: Results of a Placebo-controlled, Monosequence Crossover, Non-randomised, Single-blind Pilot Study,” Annals of the Rheumatic Diseases 68 (2009): 1613–1617.

[131] C. Cosson, R. Riou, D. Patoli, et al., “Functional Diversity of NLRP3 Gain-of-function Mutants Associated With CAPS Autoinflammation,” Journal of Experimental Medicine 221 (2024): e20231200.

[132] Q. Ma, “Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction,” Pharmacological Reviews 75 (2023): 487–520.

[133] Z. Cao, Z. Gu, S. Lin, et al., “Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6,” ACS Chemical Biology 16 (2021): 2746–2751.

[134] Q. Guo, Y. Wang, D. Xu, J. Nossent, N. J. Pavlos, and J. Xu, “Rheumatoid Arthritis: Pathological Mechanisms and Modern Pharmacologic Therapies,” Bone Research 6 (2018): 15.

[135] A. Kastbom, D. Verma, P. Eriksson, T. Skogh, G. Wingren, and P. Söderkvist, “Genetic Variation in Proteins of the Cryopyrin Inflammasome Influences Susceptibility and Severity of Rheumatoid Arthritis (the Swedish TIRA project),” Rheumatology 47 (2008): 415–417.

[136] A. Kastbom, M. Johansson, D. Verma, P. Söderkvist, and S. Rantapää-Dahlqvist, “CARD8 p.C10X Polymorphism Is Associated With Inflammatory Activity in Early Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 69 (2010): 723–726.

[137] F. Martinon, V. Pétrilli, A. Mayor, A. Tardivel, and J. Tschopp, “Gout-associated Uric Acid Crystals Activate the NALP3 Inflammasome,” Nature 440 (2006): 237–241.

[138] J. Martel-Pelletier, A. J. Barr, F. M. Cicuttini, et al., “Osteoarthritis,” Nature Reviews Disease Primers 2 (2016): 16072.

[139] M. J. McAllister, M. Chemaly, A. J. Eakin, D. S. Gibson, and V. E. McGilligan, “NLRP3 as a Potentially Novel Biomarker for the Management of Osteoarthritis,” Osteoarthritis and Cartilage 26 (2018): 612–619.

[140] A. E. Denoble, K. M. Huffman, T. V. Stabler, et al., “Uric Acid Is a Danger Signal of Increasing Risk for Osteoarthritis Through Inflammasome Activation,” PNAS 108 (2011): 2088–2093.

[141] C. Jin, P. Frayssinet, R. Pelker, et al., “NLRP3 inflammasome Plays a Critical Role in the Pathogenesis of Hydroxyapatite-associated Arthropathy,” PNAS 108 (2011): 14867–14872.

[142] C. Marchetti, B. Swartzwelter, M. I. Koenders, et al., “NLRP3 inflammasome Inhibitor OLT1177 Suppresses Joint Inflammation in Murine Models of Acute Arthritis,” Arthritis Research & Therapy 20 (2018): 169.

[143] B. Ni, W. Pei, Y. Qu, et al., “MCC950, the NLRP3 Inhibitor, Protects Against Cartilage Degradation in a Mouse Model of Osteoarthritis,” Oxidative Medicine and Cellular Longevity 2021 (2021): 4139048.

[144] E. L. Goldberg, J. L. Asher, R. D. Molony, et al., “β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares,” Cell Reports 18 (2017): 2077–2087.

[145] G. Yang, H. E. Lee, S. J. Moon, et al., “Direct Binding to NLRP3 Pyrin Domain as a Novel Strategy to Prevent NLRP3-Driven Inflammation and Gouty Arthritis,” Arthritis and Rheumatology 72 (2020): 1192–1202.

[146] V. Klück, T. Jansen, M. Janssen, et al., “Dapansutrile, an Oral Selective NLRP3 Inflammasome Inhibitor, for Treatment of Gout Flares: An Open-label, Dose-adaptive, Proof-of-concept, Phase 2a Trial,” Lancet Rheumatology 2 (2020): e270–e280.

[147] S. K. Ippagunta, D. D. Brand, J. Luo, et al., “Inflammasome-independent Role of Apoptosis-associated Speck-Like Protein Containing a CARD (ASC) in T Cell Priming Is Critical for Collagen-induced Arthritis,” Journal of Biological Chemistry 285 (2010): 12454–12462.

[148] S. Narayan, L. Kolly, A. So, and N. Busso, “Increased Interleukin-10 Production by ASC-deficient CD4+ T Cells Impairs Bystander T-cell Proliferation,” Immunology 134 (2011): 33–40.

[149] L. Pang, H. Liu, H. Quan, H. Sui, and Y. Jia, “Development of Novel Oridonin Analogs as Specifically Targeted NLRP3 Inflammasome Inhibitors for the Treatment of Dextran Sulfate Sodium-induced Colitis,” European Journal of Medicinal Chemistry 245 (2023): 114919.

[150] C. He, J. Liu, J. Li, et al., “Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors With Potent Anti-Inflammation Activity,” Journal of Medicinal Chemistry 67 (2024): 9406–9430.

[151] A. C. Villani, M. Lemire, G. Fortin, et al., “Common Variants in the NLRP3 Region Contribute to Crohn's Disease Susceptibility,” Nature Genetics 41 (2009): 71–76.

[152] L. Mao, A. Kitani, M. Similuk, et al., “Loss-of-function CARD8 Mutation Causes NLRP3 Inflammasome Activation and Crohn's Disease,” Journal of Clinical Investigation 128 (2018): 1793–1806.

[153] X. Liu, Y. Fang, X. Lv, et al., “Deubiquitinase OTUD6A in Macrophages Promotes Intestinal Inflammation and Colitis via Deubiquitination of NLRP3,” Cell Death and Differentiation 30 (2023): 1457–1471.

[154] J. Zhao, Z. Zhao, P. Ying, et al., “METTL3-mediated M(6) A Modification of circPRKAR1B Promotes Crohn's Colitis by Inducing Pyroptosis via Autophagy Inhibition,” Clinical and Translational Medicine 13 (2023): e1405.

[155] L. Kolly, M. Karababa, L. A. Joosten, et al., “Inflammatory Role of ASC in Antigen-induced Arthritis is Independent of Caspase-1, NALP-3, and IPAF,” Journal of Immunology 183 (2009): 4003–4012.

[156] F. Zhang, W. Zhao, J. Zhou, et al., “Heat Shock Transcription Factor 2 Reduces the Secretion of IL-1β by Inhibiting NLRP3 Inflammasome Activation in Ulcerative Colitis,” Gene 768 (2021): 145299.

[157] X. Shao, S. Sun, Y. Zhou, et al., “Bacteroides fragilis Restricts Colitis-associated Cancer via Negative Regulation of the NLRP3 Axis,” Cancer Letters 523 (2021): 170–181.

[158] P. Li, G. Chen, J. Zhang, et al., “Live Lactobacillus Acidophilus Alleviates Ulcerative Colitis via the SCFAs/Mitophagy/NLRP3 Inflammasome Axis,” Food and Functions 13 (2022): 2985–2997.

[159] A. Promoda Perera, R. Fernando, T. Shinde, et al., “Rajaraman Eri, MCC950, a Specific Small Molecule Inhibitor of NLRP3 Inflammasome Attenuates Colonic Inflammation in Spontaneous Colitis Mice,” Scientific Reports 8 (2018): 8618.

[160] B. Klughammer, L. Piali, A. Nica, et al., “A Randomized, Double-blind Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the NLRP3 Inhibitor Selnoflast in Patients With Moderate to Severe Active Ulcerative Colitis,” Clinical and Translational Medicine 13 (2023): e1471.

[161] I. Haque, P. Thapa, D. M. Burns, et al., “NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development,” International Journal of Molecular Sciences 25 (2024): 6078.

[162] K. Yin, Z. Zhang, Y. Mo, et al., “Discovery of Autophagy-tethering Compounds as Potent NLRP3 Degraders for IBD Immunotherapy,” European Journal of Medicinal Chemistry 275 (2024): 116581.

[163] P. Theofilis, E. Oikonomou, C. Chasikidis, K. Tsioufis, and D. Tousoulis, “Inflammasomes in Atherosclerosis-From Pathophysiology to Treatment,” Pharmaceuticals 16 (2023): 1211.

[164] Y. Jin and J. Fu, “Novel Insights into the NLRP3 Inflammasome in Atherosclerosis,” Journal of the American Heart Association 8 (2019): e012219.

[165] D. Xie, H. Guo, M. Li, et al., “Splenic Monocytes Mediate Inflammatory Response and Exacerbate Myocardial Ischemia/Reperfusion Injury in a Mitochondrial Cell-free DNA-TLR9-NLRP3-dependent Fashion,” Basic Research in Cardiology 118 (2023): 44.

[166] G. F. Wohlford, B. W. V. Tassell, H. E. Billingsley, et al., “Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects with NYHA II–III Systolic Heart Failure,” Journal of Cardiovascular Pharmacology 77 (2021): 49.

[167] Q. Luo, L. Dai, J. Li, et al., “Intracellular and Extracellular Synergistic Therapy for Restoring Macrophage Functions via Anti-CD47 Antibody-conjugated Bifunctional Nanoparticles in Atherosclerosis,” Bioactive Materials 34 (2024): 326–337.

[168] Y. Liu, K. Lian, L. Zhang, et al., “TXNIP Mediates NLRP3 Inflammasome Activation in Cardiac Microvascular Endothelial Cells as a Novel Mechanism in Myocardial Ischemia/Reperfusion Injury,” Basic Research in Cardiology 109 (2014): 415.

[169] S. Sano, K. Oshima, Y. Wang, et al., “Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure through a Mechanism Involving the IL-1β/NLRP3 Inflammasome,” Journal of the American College of Cardiology 71 (2018): 875–886.

[170] S. Toldo, A. G. Mauro, Z. Cutter, et al., “The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function after Ischemia Reperfusion Injury in the Mouse,” Journal of Cardiovascular Pharmacology 73 (2019): 215–222.

[171] S. Chen, Y. Wang, Y. Pan, et al., “Novel Role for Tranilast in Regulating NLRP3 Ubiquitination, Vascular Inflammation, and Atherosclerosis,” Journal of the American Heart Association 9 (2020): e015513.

[172] M. Lamkanfi, J. L. Mueller, A. C. Vitari, et al., “Glyburide Inhibits the Cryopyrin/Nalp3 Inflammasome,” Journal of Cell Biology 187 (2009): 61–70.

[173] S. Nizami, V. Millar, K. Arunasalam, et al., “A Phenotypic High-content, High-throughput Screen Identifies Inhibitors of NLRP3 Inflammasome Activation,” Scientific Reports 11 (2021): 15319.

[174] C. Dekker, H. Mattes, M. Wright, et al., “Crystal Structure of NLRP3 NACHT Domain with an Inhibitor Defines Mechanism of Inflammasome Inhibition,” Journal of Molecular Biology 433 (2021): 167309.

[175] C. McBride, L. Trzoss, D. Povero, et al., “Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]Oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor,” Journal of Medicinal Chemistry 65 (2022): 14721–14739.

[176] F. Tang, R. Kunder, T. Chu, et al., “First-in-human Phase 1 Trial Evaluating Safety, Pharmacokinetics, and Pharmacodynamics of NLRP3 Inflammasome Inhibitor, GDC-2394, in Healthy Volunteers,” Clinical and Translational Science 16 (2023): 1653–1666.

[177] M. Isazadeh, M. Amandadi, F. Haghdoust, S. Lotfollazadeh, M. Orzáez, and S. Hosseinkhani, “Split-luciferase Complementary Assay of NLRP3 PYD-PYD Interaction Indicates Inflammasome Formation During Inflammation,” Analytical Biochemistry 638 (2022): 114510.

[178] H. Jiang, H. He, Y. Chen, et al., “Identification of a Selective and Direct NLRP3 Inhibitor to Treat Inflammatory Disorders,” Journal of Experimental Medicine 214 (2017): 3219–3238.

[179] K. C. Liao, C. F. Sandall, D. A. Carlson, et al., “Application of Immobilized ATP to the Study of NLRP Inflammasomes,” Archives of Biochemistry and Biophysics 670 (2019): 104–115.

[180] C. Hayat, V. Subramaniyan, M. A. Alamri, et al., “Identification of New Potent NLRP3 Inhibitors by Multi-level in-silico Approaches,” BMC Chemistry 18 (2024): 76.

[181] P. Qin, Y. Niu, J. Duan, and P. Lin, “Computational Study on the Mechanism of Small Molecules Inhibiting NLRP3 With Ensemble Docking and Molecular Dynamic Simulations,” BMC Pharmacology and Toxicology 26 (2025): 49.

[182] C. Shi, T. Gao, W. Lyu, et al., “Deep-Learning-Driven Discovery of SN3-1, a Potent NLRP3 Inhibitor With Therapeutic Potential for Inflammatory Diseases,” Journal of Medicinal Chemistry 67 (2024): 17833–17854.

[183] R. C. Coll, A. A. Robertson, J. J. Chae, et al., “A Small-molecule Inhibitor of the NLRP3 Inflammasome for the Treatment of Inflammatory Diseases,” Nature Medicine 21 (2015): 248–255.

[184] E. A. Caseley, J. A. Poulter, F. Rodrigues, and M. F. McDermott, “Inflammasome Inhibition Under Physiological and Pharmacological Conditions,” Genes and Immunity 21 (2020): 211–223.

[185] A. Sylvain, N. Stoehr, F. Ma, et al., “A Cereblon-based Glue Degrader of NEK7 Regulates NLRP3 Inflammasome in a Context-dependent Manner,” Cell Chemical Biology 32 (2025): 955–968.

[186] B. A. McKenzie, M. K. Mamik, L. B. Saito, et al., “Caspase-1 Inhibition Prevents Glial Inflammasome Activation and Pyroptosis in Models of Multiple Sclerosis,” PNAS 115 (2018): E6065–e6074.

[187] Z. Dai, W. C. Liu, X. Y. Chen, X. Wang, J. L. Li, and X. Zhang, “Gasdermin D-mediated Pyroptosis: Mechanisms, Diseases, and Inhibitors,” Frontiers in Immunology 14 (2023): 1178662.

[188] J. Xu, J. M. Pickard, and G. Núñez, “FDA-approved Disulfiram Inhibits the NLRP3 Inflammasome by Regulating NLRP3 Palmitoylation,” Cell Reports 43 (2024): 114609.

[189] D. D. Arnold, A. Yalamanoglu, and O. Boyman, “Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders,” Frontiers in Immunology 13 (2022): 888392.

[190] G. Fenini, E. Contassot, and L. E. French, “Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases,” Frontiers in Pharmacology 8 (2017): 278.

[191] A. Gombault, L. Baron, and I. Couillin, “ATP Release and Purinergic Signaling in NLRP3 Inflammasome Activation,” Frontiers in Immunology 3 (2012): 414.

[192] J. J. Martínez-García, H. Martínez-Banaclocha, D. Angosto-Bazarra, et al., “P2×7 receptor Induces Mitochondrial Failure in Monocytes and Compromises NLRP3 Inflammasome Activation During Sepsis,” Nature Communications 10 (2019): 2711.

[193] M. Biasizzo and N. Kopitar-Jerala, “Interplay between NLRP3 Inflammasome and Autophagy,” Frontiers in Immunology 11 (2020): 591803.

[194] T. Keuler, D. Ferber, J. Engelhardt, et al., “Degrading the Key Component of the Inflammasome: Development of an NLRP3 PROTAC,” Chemical Communications 61 (2025): 3001–3004.

[195] L. Wang and J. Cui, “Palmitoylation Promotes Chaperone-mediated Autophagic Degradation of NLRP3 to Modulate Inflammation,” Autophagy 19 (2023): 2821–2823.

[196] E. Gatlik, B. Mehes, E. Voltz, et al., “First-in-human Safety, Tolerability, and Pharmacokinetic Results of DFV890, an Oral Low-molecular-weight NLRP3 Inhibitor,” Clinical and Translational Science 17 (2024): e13789.

[197] E. A. Albornoz, K. Mardon, R. Bhalla, et al., “PET-MRI Biomarkers Reveal Efficacy of a Novel NLRP3 Inhibitor in Parkinson's disease Models,” Brain (2025): awaf372. Epub ahead of print.

[198] R. C. Coll, K. Schroder, and P. Pelegrín, “NLRP3 and Pyroptosis Blockers for Treating Inflammatory Diseases,” Trends in Pharmacological Sciences 43 (2022): 653–668.

[199] D. Harrison, A. Billinton, M. G. Bock, et al., “Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders,” Journal of Medicinal Chemistry 66 (2023): 14897–14911.

[200] C. Marchetti, B. Swartzwelter, F. Gamboni, et al., “OLT1177, a β-sulfonyl Nitrile Compound, Safe in Humans, Inhibits the NLRP3 Inflammasome and Reverses the Metabolic Cost of Inflammation,” PNAS 115 (2018): E1530–E1539.

[201] N. Lonnemann, S. Hosseini, C. Marchetti, et al., “The NLRP3 Inflammasome Inhibitor OLT1177 Rescues Cognitive Impairment in a Mouse Model of Alzheimer's Disease,” PNAS 117 (2020): 32145–32154.

[202] A. Sánchez-Fernández, D. B. Skouras, C. A. Dinarello, and R. López-Vales, “OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis,” Frontiers in Immunology 10 (2019): 2578.

[203] J. Velcicky, P. Janser, N. Gommermann, et al., “Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors,” Journal of Medicinal Chemistry 67 (2024): 1544–1562.

[204] Z. Fu, Y. Duan, H. Pei, et al., “Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and Peritonitis,” Journal of Medicinal Chemistry 67 (2024): 15711–15737.

[205] H. He, H. Jiang, Y. Chen, et al., “Oridonin Is a Covalent NLRP3 Inhibitor With Strong Anti-inflammasome Activity,” Nature Communications 9 (2018): 2550.

[206] M. Li, L. Ma, J. Lv, et al., “Design, Synthesis, and Biological Evaluation of Oridonin Derivatives as Novel NLRP3 Inflammasome Inhibitors for the Treatment of Acute Lung Injury,” European Journal of Medicinal Chemistry 277 (2024): 116760.

[207] B. Oronsky, L. Takahashi, R. Gordon, P. Cabrales, S. Caroen, and T. Reid, “RRx-001: A Chimeric Triple Action NLRP3 Inhibitor, Nrf2 Inducer, and Nitric Oxide Superagonist,” Frontiers in Oncology 13 (2023): 1204143.

[208] Y. Shi, Q. Lv, M. Zheng, H. Sun, and F. Shi, “NLRP3 inflammasome Inhibitor INF39 Attenuated NLRP3 Assembly in Macrophages,” International Immunopharmacology 92 (2021): 107358.

[209] M. Cocco, C. Pellegrini, H. Martínez-Banaclocha, et al., “Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease,” Journal of Medicinal Chemistry 60 (2017): 3656–3671.

[210] X. Zhang, L. Hu, S. Xu, C. Ye, and A. Chen, “Erianin: A Direct NLRP3 Inhibitor with Remarkable Anti-Inflammatory Activity,” Frontiers in Immunology 12 (2021): 739953.

[211] H. Xu, J. Chen, P. Chen, et al., “Costunolide Covalently Targets NACHT Domain of NLRP3 to Inhibit Inflammasome Activation and Alleviate NLRP3-driven Inflammatory Diseases,” Acta Pharmaceutica Sinica B 13 (2023): 678–693.

[212] A. Hooftman, S. Angiari, S. Hester, et al., “The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation,” Cell Metabolism 32 (2020): 468–478.

[213] C. Molina-Lopez, L. Hurtado-Navarro, and L. A. J. O'Neill, “Pelegrin, 4-octyl Itaconate Reduces human NLRP3 Inflammasome Constitutive Activation With the Cryopyrin-associated Periodic Syndrome p.R262W, p.D305N and p.T350M Variants,” Cellular and Molecular Life Sciences 82 (2025): 209.

[214] N. Kaneko, M. Kurata, T. Yamamoto, et al., “KN3014, a Piperidine-containing Small Compound, Inhibits Auto-secretion of IL-1β From PBMCs in a Patient With Muckle-Wells syndrome,” Scientific Reports 10 (2020): 13562.

[215] C. Shi, X. Zhang, X. Chi, et al., “Discovery of NLRP3 Inhibitors Using Machine Learning: Identification of a Hit Compound to Treat NLRP3 Activation-driven Diseases,” European Journal of Medicinal Chemistry 260 (2023): 115784.

[216] Y. Xu, Y. Xu, S. Biby, et al., “Design and Discovery of Novel NLRP3 Inhibitors and PET Imaging Radiotracers Based on a 1,2,3-Triazole-Bearing Scaffold,” Journal of Medicinal Chemistry 67 (2024): 555–571.

[217] J. Zhao, Y. Li, J. Ma, et al., “Synthesis and Pharmacological Validation of Fluorescent Diarylsulfonylurea Analogues as NLRP3 Inhibitors and Imaging Probes,” European Journal of Medicinal Chemistry 237 (2022): 114338.

[218] A. Saeedi-Boroujeni, M. R. Mahmoudian-Sani, R. Nashibi, S. Houshmandfar, S. Tahmaseby Gandomkari, and A. Khodadadi, “Tranilast: A Potential Anti-Inflammatory and NLRP3 Inflammasome Inhibitor Drug for COVID-19,” Immunopharmacology and Immunotoxicology 43 (2021): 247–258.

[219] Y. Huang, H. Jiang, Y. Chen, et al., “Tranilast Directly Targets NLRP3 to Treat Inflammasome-driven Diseases,” EMBO Molecular Medicine 10 (2018): e8689.

[220] E. Rabinovich, A. Fromowitz, O. Ajibade, et al., “The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML,” Blood 142 (2023): 1417–1417.

[221] H. Lin, M. Yang, C. Li, et al., “An RRx-001 Analogue with Potent Anti-NLRP3 Inflammasome Activity but without High-Energy Nitro Functional Groups,” Frontiers in Pharmacology 13 (2022): 822833.

[222] A. Tapia-Abellan, D. Angosto-Bazarra, H. Martinez-Banaclocha, et al., “MCC950 closes the Active Conformation of NLRP3 to an Inactive state,” Nature Chemical Biology 15 (2019): 560–564.

[223] L. Vande Walle, I. B. Stowe, P. Šácha, et al., “MCC950/CRID3 potently Targets the NACHT Domain of Wild-type NLRP3 but Not Disease-associated Mutants for Inflammasome Inhibition,” PloS Biology 17 (2019): e3000354.

[224] I. V. Hochheiser, M. Pilsl, G. Hagelueken, et al., “Structure of the NLRP3 Decamer Bound to the Cytokine Release Inhibitor CRID3,” Nature 604 (2022): 184–189.

[225] C. R. Kennedy, A. Goya Grocin, T. Kovačič, et al., “A Probe for NLRP3 Inflammasome Inhibitor MCC950 Identifies Carbonic Anhydrase 2 as a Novel Target,” ACS Chemical Biology 16 (2021): 982–990.

[226] M. S. J. Mangan, E. J. Olhava, W. R. Roush, H. M. Seidel, G. D. Glick, and E. Latz, “Targeting the NLRP3 Inflammasome in Inflammatory Diseases,” Nature Reviews Drug Discovery 17 (2018): 688.

[227] T. Keuler, D. Ferber, M. Marleaux, M. Geyer, and M. Gütschow, “Structure–Stability Relationship of NLRP3 Inflammasome-Inhibiting Sulfonylureas,” ACS Omega 7 (2022): 8158–8162.

[228] M. Salla, M. S. Butler, N. L. Massey, J. C. Reid, M. A. Cooper, and A. A. B. Robertson, “Synthesis of Deuterium-labelled Analogues of NLRP3 Inflammasome Inhibitor MCC950,” Bioorganic & Medicinal Chemistry Letters 28 (2018): 793–795.

[229] S. Agarwal, S. Sasane, H. A. Shah, et al., “Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors,” ACS Medicinal Chemistry Letters 11 (2020): 414–418.

[230] J. R. Hill, R. C. Coll, N. Sue, et al., “Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors,” ChemMedChem 12 (2017): 1449–1457.

[231] V. Albanese, S. Missiroli, M. Perrone, et al., “Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer,” Journal of Medicinal Chemistry 66 (2023): 5223–5241.

[232] D. Harrison, N. Boutard, K. Brzozka, et al., “Discovery of a Series of Ester-substituted NLRP3 Inflammasome Inhibitors,” Bioorganic & Medicinal Chemistry Letters 30 (2020): 127560.

[233] P. Narros-Fernández, M. Chioua, S. A. Petcu, et al., “Synthesis and Pharmacological Evaluation of New N-Sulfonylureas as NLRP3 Inflammasome Inhibitors: Identification of a Hit Compound to Treat Gout,” Journal of Medicinal Chemistry 65 (2022): 6250–6260.

[234] Z. Li, Y. Chen, X. Jiang, et al., “Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis,” Journal of Medicinal Chemistry 66 (2023): 12966–12989.

[235] E. Gatlik, B. Mehes, E. Voltz, et al., “First-in-human Safety, Tolerability, and Pharmacokinetic Results of DFV890, an Oral Low-molecular-weight NLRP3 Inhibitor,” Clinical and Translational Science 17 (2024): e13789.

[236] N. Clarke, P. Thornton, V. Reader, et al., “Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects With Parkinson's Disease,” Movement Disorders 40 (2025): 2199–2208.

[237] R. Ramachandran, A. Manan, J. Kim, and S. Choi, “NLRP3 inflammasome: A Key Player in the Pathogenesis of Life-style Disorders,” Experimental & Molecular Medicine 56 (2024): 1488–1500.

[238] Y. Xu, S. Biby, B. Kaur, and S. Zhang, “A Patent Review of NLRP3 Inhibitors to Treat Autoimmune Diseases,” Expert Opinion on Therapeutic Patents 33 (2023): 455–470.

[239] J. E. Cabral, A. Wu, H. Zhou, M. A. Pham, S. Lin, and R. McNulty, “Targeting the NLRP3 Inflammasome for Inflammatory Disease Therapy,” Trends in Pharmacological Sciences 46 (2025): 503–519.

[240] K. A. Teske, C. Corona, J. Wilkinson, et al., “Interrogating Direct NLRP3 Engagement and Functional Inflammasome Inhibition Using Cellular Assays,” Cell Chemical Biology 31 (2024): 349–360.e6.

[241] C. Marchetti, B. Swartzwelter, M. I. Koenders, et al., “NLRP3 inflammasome Inhibitor OLT1177 Suppresses Joint Inflammation in Murine Models of Acute Arthritis,” Arthritis Research & Therapy 20 (2018): 1–11.

[242] Y. Chen, H. He, H. Jiang, et al., “Discovery and Optimization of 4-oxo-2-thioxo-thiazolidinones as NOD-Like Receptor (NLR) family, Pyrin Domain-containing Protein 3 (NLRP3) Inhibitors,” Bioorganic & Medicinal Chemistry Letters 30 (2020): 127021.

[243] S. Gastaldi, V. Boscaro, E. Gianquinto, et al., “Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]Imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor,” Molecules 26 (2021): 3975.

[244] X. Li, C.-T. Zhang, W. Ma, X. Xie, and Q. Huang, “Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity,” Frontiers in Pharmacology 12 (2021): 2021.

[245] B. Oronsky, L. Takahashi, R. Gordon, P. Cabrales, S. Caroen, and T. Reid, “RRx-001: A Chimeric Triple Action NLRP3 Inhibitor, Nrf2 Inducer, and Nitric Oxide Superagonist,” Frontiers in Oncology 13 (2023): 2023.

[246] C. G. Li, L. Yan, F. Y. Mai, et al., “Baicalin Inhibits NOD-Like Receptor Family, Pyrin Containing Domain 3 Inflammasome Activation in Murine Macrophages by Augmenting Protein Kinase A Signaling,” Frontiers in Immunology 8 (2017): 1409.

[247] S. Y. Chen, Y. P. Li, Y. P. You, et al., “Theaflavin Mitigates Acute Gouty Peritonitis and Septic Organ Injury in Mice by Suppressing NLRP3 Inflammasome Assembly,” Acta Pharmacologica Sinica 44 (2023): 2019–2036.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.